Literature DB >> 32228228

In vitro synergistic activity of fosfomycin in combination with meropenem, amikacin and colistin against OXA-48 and/or NDM-producing Klebsiella pneumoniae.

Buket Erturk Sengel1, Gulsen Altinkanat Gelmez2, Guner Soyletir2, Volkan Korten1.   

Abstract

Objective: Carbapenemase-producing Klebsiella pneumoniae (CPKp) infections are increasing worldwide. We investigated the in vitro synergistic activity of fosfomycin (FOS) with meropenem (MRP), amikacin (AMK) and colistin (COL) against OXA-48 and/or New Delhi metallo-beta-lactamase (NDM)-producing Kp blood isolates. Materials and
Methods: Seventeen CPKp blood isolates were studied. The broth microdilution method was used for COL, MRP and AMK susceptibilities, while agar dilution for FOS. Synergy was tested by agar dilution chequerboard technique and also was confirmed by a time-kill assay for FOS/MRP and FOS/COL using three representative isolates that were found to be synergistic.
Results: FOS in combination with MRP was found to be the most synergistic (15/17 strains, 88%), while 29% and 41% with AMK and COL, respectively. Antagonism was only determined in 2 isolates with the COL/FOS. Conclusions: The MRP/FOS combination demonstrated synergistic activity against CRKp, especially against the two common enzyme-producing isolates in Turkey (OXA-48 and NDM).

Entities:  

Keywords:  Antagonism; In Vitro synergy; Klebsiella pneumoniae; antibiotic resistance; arbapenemase; fosfomycin

Mesh:

Substances:

Year:  2020        PMID: 32228228     DOI: 10.1080/1120009X.2020.1745501

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  6 in total

1.  Synergistic antibacterial effects of colistin in combination with aminoglycoside, carbapenems, cephalosporins, fluoroquinolones, tetracyclines, fosfomycin, and piperacillin on multidrug resistant Klebsiella pneumoniae isolates.

Authors:  Julalak C Ontong; Nwabor F Ozioma; Supayang P Voravuthikunchai; Sarunyou Chusri
Journal:  PLoS One       Date:  2021-01-06       Impact factor: 3.240

2.  Evaluation of the Synergistic Antibacterial Effects of Fosfomycin in Combination with Selected Antibiotics against Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Ozioma F Nwabor; Pawarisa Terbtothakun; Supayang P Voravuthikunchai; Sarunyou Chusri
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-25

3.  Prediction of Prognosis in Adult Patients With Carbapenem-Resistant Klebsiella pneumoniae Infection.

Authors:  Jihui Chen; Yu Yang; Huimin Yao; Shuhong Bu; Lixia Li; Fang Wang; Feng Chen; Huijuan Yao
Journal:  Front Cell Infect Microbiol       Date:  2022-01-11       Impact factor: 5.293

4.  Assessment of In-Vitro Synergy of Fosfomycin with Meropenem, Amikacin and Tigecycline in Whole Genome Sequenced Extended and Pan Drug Resistant Klebsiella Pneumoniae: Exploring A Colistin Sparing Protocol.

Authors:  Manawr Al-Quraini; Meher Rizvi; Zaaima Al-Jabri; Hiba Sami; Muna Al-Muzahmi; Zakariya Al-Muharrmi; Neelam Taneja; Ibrahim Al-Busaidi; Rajeev Soman
Journal:  Antibiotics (Basel)       Date:  2022-01-25

Review 5.  Losing the Battle but Winning the War: Can Defeated Antibacterials Form Alliances to Combat Drug-Resistant Pathogens?

Authors:  Song Oh; Raymond Chau; Anh T Nguyen; Justin R Lenhard
Journal:  Antibiotics (Basel)       Date:  2021-05-28

Review 6.  Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.

Authors:  Stamatis Karakonstantis; Evangelos I Kritsotakis; Achilleas Gikas
Journal:  Infection       Date:  2020-09-01       Impact factor: 3.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.